Tom van der Hulle
Overview
Explore the profile of Tom van der Hulle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Op t Hoog C, Rieborn A, Moes D, Hendrikx J, van der Heijden M, Franken M, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):36.
PMID: 39998586
Aim: Enfortumab vedotin is an antibody-drug conjugate (ADC) that has been approved for locally advanced or metastatic urothelial cancer, as monotherapy and in combination with pembrolizumab, and has shown significant...
2.
Vrancken Peeters N, Kerklaan R, Vlooswijk C, Bijlsma R, Kaal S, Tromp J, et al.
Qual Life Res
. 2025 Feb;
PMID: 39982594
Purpose: As the prognosis for adolescents and young adults (AYAs) with breast cancer has improved, long-term health-related quality of life (HRQoL) has become increasingly important. This study aimed to analyze...
3.
Kleiburg F, de Geus-Oei L, Spijkerman R, Noortman W, van Velden F, Manohar S, et al.
Eur Radiol
. 2025 Jan;
PMID: 39843627
Objective: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with varying survival outcomes. This study investigated whether baseline PSMA PET/CT parameters are associated with survival and treatment response. Methods:...
4.
Angoumis K, Padilla C, Kouwenhoven M, Bijlsma R, Kaal S, Tromp J, et al.
Support Care Cancer
. 2025 Jan;
33(2):95.
PMID: 39808329
Purpose: Adolescent and young adult (AYA) malignant brain tumour (BT) survivors are at risk of adverse health outcomes, which may impact their health-related quality of life (HRQoL). This study aimed...
5.
Tan Z, Voller S, Yin A, Rieborn A, Gelderblom A, van der Hulle T, et al.
Clin Pharmacokinet
. 2024 Jun;
63(6):857-869.
PMID: 38874883
Introduction: Cabozantinib is one of the preferred treatment options in the latest metastatic renal cell carcinoma (mRCC) guidelines. Cabozantinib is also associated with high drug expenses irrespective of the used...
6.
Janssen S, Vlooswijk C, Bijlsma R, Kaal S, Kerst J, Tromp J, et al.
J Cancer Surviv
. 2024 May;
PMID: 38740702
Background: With 5-year survival rates > 85%, gaining insight into the long-term and late health-related conditions of cancer survivors diagnosed in adolescence and young adulthood is of utmost importance to...
7.
Chen Q, van Rein N, van der Hulle T, Heemelaar J, Trines S, Versteeg H, et al.
Eur Heart J
. 2024 Apr;
45(25):2201-2213.
PMID: 38619538
Background And Aims: Coexisting atrial fibrillation (AF) and cancer challenge the management of both. The aim of the study is to comprehensively provide the epidemiology of coexisting AF and cancer....
8.
Hendriks P, Rietbergen D, van Erkel A, Coenraad M, Arntz M, Bennink R, et al.
Eur J Nucl Med Mol Imaging
. 2024 Feb;
51(7):2085-2097.
PMID: 38329507
Purpose: The aim of this study was to investigate the biodistribution of (super-)selective trans-arterial radioembolization (TARE) with holmium-166 microspheres (Ho-MS), when administered as adjuvant therapy after RFA of HCC 2-5...
9.
Lehmann V, Vlooswijk C, van der Graaf W, Bijlsma R, Kaal S, Kerst J, et al.
J Cancer Surviv
. 2024 Feb;
PMID: 38316726
Purpose: To describe recall of fertility-related consultations and cryopreservation and to examine reproductive goals and reproduction post-treatment in long-term survivors of adolescent and young adult (AYA) (age, 18-39 years) cancer....
10.
Gavioli C, Vlooswijk C, Janssen S, Kaal S, Kerst J, Tromp J, et al.
J Cancer Surviv
. 2024 Jan;
PMID: 38224397
Purpose: For adolescent and young adult (AYA) cancer survivors with a good prognosis, having a healthy lifestyle prevents morbidity and mortality after treatment. The aim of this study was to...